Wire · operational-macro
Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Karyopharm Therapeutics has filed for Chapter 11 bankruptcy and plans to merge with Irish biotech Ayrmid, which is positioned as the lead bidder in a court-supervised sale process allowing competing offers. The restructuring aims to sustain Karyopharm's hematology drug pipeline, including its multiple myeloma treatment Xpovio, while securing debtor-in-possession financing to maintain operations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech with a weakening balance sheet now faces court-driven asset sales and potential new ownership that can keep key drug candidates alive. Prepare for shifts in partnership and customer relations as buyers compete and financing tightens under court supervision.
◆ Coverage
1 source · 2 Nov 2026
◆ Related on Wire
◆ Topics